Journal of Clinical & Experimental Dermatology Research
Open Access

Halobetasol propionate loaded nanostructured lipid carriers for topical delivery

Vitiligo and Skincare Physicians Meeting

September 15-16, 2016 Berlin, Germany

Paulina Andrea Carvajal Vidal, M Garcia, M Espina and A Calpena

University of Barcelona, Spain

Posters & Accepted Abstracts: J Clin Exp Dermatol Res

Abstract :

Vitiligo is a skin disorder with estimated prevalence of 1% of worldwide population and is characterized by depigmented macules due to the loss of functionality or destruction of melanocytes. The etiology is unknown, but one hypothesis is an autoimmune pathogenesis. Several treatments have been tested for this skin disorder, including psoralens, UVA therapy and steroids. Halobetasol propionate (Hb) is a potent corticosteroid commonly used for skin diseases such as eczema, rash and vitiligo, as initial treatment because of the severe side effects that may occur. To improve this characteristic, it is necessary to develop a controlled release system for this type of drugs. Nanostructured lipid carriers (NLC) constitute an alternative to improve drug delivery and decrease secondary effects. The purpose of this study was to design and optimize a formulation of NLC for topical delivery of HB based on lipid nanoparticles. This NLC were composed of Precirol, LAS and Tween 80 and the hot high pressure homogenization method was used. A factorial design based on three variables was used to plan the experiments, namely, amount of lipid, HB concentration and stabilizer concentration. The results showed that increasing lipid amount was followed by an enhanced tendency to produce larger particles with small polydispersity index (PI). The selected formulation showed size <200 nm; PI <0.230; Zp ~15 mV and Encapsulation efficiency (EE) >90%. These results are acceptable parameters for a formulation for topical delivery and are an alternative for controlled release of Hb.

Biography :

Paulina Andrea Carvajal Vidal is a Pharmacist from Chile. She has completed her Master’s degree of “Investigation, Development and Control of Medicines” and currently pursuing PhD at the Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry at Barcelona University. Her studies are focused on the field of lipid nanoparticles for topical delivery, the utilization of corticosteroids and skin diseases.

Email: paulina.carvajalv@gmail.com